In 181 adults with asthma on maintenance inhaled corticosteroids, budesonide-formoterol reliever reduced geometric mean FeNO by 18.50% versus terbutaline reliever at 26 weeks (phase 4, open-label); adverse events were similar (83% vs 78%).
RCTn = 181
Noble et al. Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial